TIDMAGL
Angle PLC
22 January 2024
For immediate release 22 January 2024
ANGLE plc ("the Company")
REVIEW PAPER ON MOLECULAR ANALYSIS OF PARSORTIX CTC HARVEST
HIGHLIGHTS POTENTIAL UTILITY IN PRECISION ONCOLOGY
Paper published in the journal "Current Issues in Molecular
Biology" special issue: advanced solutions for cancer therapy
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company with innovative circulating tumour cell (CTC) diagnostic
solutions for use in research, drug development and clinical
oncology, is pleased to announce the publication of a peer-reviewed
paper in a special issue of the journal - "Current Issues in
Molecular Biology" Special Issue: Advanced Solutions for Cancer
Therapy.
ANGLE recently announced breakthrough data from a newly
established workflow for real-time parallel Next Generation
Sequencing (NGS) DNA analysis of both ctDNA (fragments of DNA
released mainly by dying cells) and CTCs (living cancer cells) from
a single tube of patient blood, using a pan-cancer panel run on an
Illumina NGS system. This peer-reviewed article brings together
supporting evidence for the additional and complementary
information that can be obtained from CTCs using the Parsortix(R)
system, demonstrating the value of a dual analyte approach for both
CTCs and ctDNA.
The review article details research from multiple independent,
leading cancer centres, such as The University of Athens, Greece,
University Medical Center Hamburg-Eppendorf, Germany, Fondazione
IRCCS Istituto Nazionale dei Tumori, Italy, the Health Research
Institute of Santiago (IDIS), Spain and Edith Cowan University,
Australia. The benefits of utilising the Parsortix system for
downstream molecular analysis is showcased across these cancer
centres in various cancer types including non-small cell lung
cancer, triple negative breast cancer, head and neck cancer,
colorectal cancer, and melanoma, highlighting the wide utility of
the Parsortix system.
In support of ANGLE's breakthrough data, DNA variants were
identified in some studies that were exclusive to CTCs, as compared
to ctDNA, and the combined molecular analysis of CTCs and ctDNA in
a research setting increased the number of patients identified with
a potentially actionable biomarker, providing a more comprehensive
gene variant profile. This enhanced gene variant profile has the
potential, subject to further study, to inform on prognosis,
treatment selection, monitoring of treatment resistance and disease
relapse.
The Parsortix system is identified as the optimal technology for
this purpose as, with Parsortix label-free microfluidic isolation,
all phenotypes of CTCs can be harvested intact and undamaged
providing easily accessible samples for molecular analysis with low
white blood cell background.
The review article contextualises these findings within the
field of liquid biopsies, highlighting the shift in understanding
that CTCs and ctDNA can provide complementary and additive
information. Harvested CTCs also have the added advantage in that
they can undergo RNA, protein, and morphological analysis, thus
combining genotype with phenotype to give a comprehensive biomarker
profile. These recent advances in molecular oncology, combined with
broad phenotyping including protein expression and analysis of
methylation patterns are driving the implementation of precision
oncology, with the aim of improving patient care.
The peer-reviewed journal article entitled "Molecular Profiling
of Circulating Tumour Cells and Circulating Tumour DNA:
Complementary Insights from a Single Blood Sample Utilising the
Parsortix System" is available through Open Access and is available
on the Company's website: www.angleplc.com/publications/
ANGLE Chief Scientific Officer, Karen Miller, commented:
"As the revolution in 'omics' data evolves, the importance of
CTCs to extract genomic and phenotypic profiling information is
becoming increasingly evident, providing valuable and potentially
actionable data that, subject to further study, may be used to
guide patient management decisions in a way that is not possible
using only ctDNA."
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Berenberg (NOMAD and Broker)
Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative
circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology using a simple
blood sample. ANGLE's FDA cleared and patent protected circulating
tumour cell (CTC) harvesting technology known as the Parsortix(R)
PC1 System enables complete downstream analysis of the sample
including whole cell imaging and proteomic analysis and full
genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic
products and clinical services. Diagnostic products include the
Parsortix(R) system and associated consumables. The clinical
services business is offered through ANGLE's GCP-compliant
laboratories. Services include custom made assay development and
clinical trial testing for pharma.
Over 90 peer-reviewed publications have demonstrated the
performance of the Parsortix system. For more information, visit
www.angleplc.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPUACGUPCGMB
(END) Dow Jones Newswires
January 22, 2024 02:00 ET (07:00 GMT)
Grafico Azioni Angle (LSE:AGL)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Angle (LSE:AGL)
Storico
Da Dic 2023 a Dic 2024
